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Care in Diabetes—2009
Current Criteria for the Diagnosis of
Diabetes
● Fasting plasma glucose (FPG) 126
mg/dl (7.0 mmol/l). Fasting is deﬁned
as no caloric intake for at least 8 h
● Symptoms of hyperglycemia and a ca-
sual (random) plasma glucose 200
mg/dl (11.1 mmol/l). Casual (random)
is deﬁned as any time of day without
regard to time since last meal. The clas-
sicsymptomsofhyperglycemiainclude
polyuria, polydipsia, and unexplained
weight loss.
● 2-h plasma glucose 200 mg/dl (11.1
mmol/l) during an oral glucose toler-
ance test (OGTT). The test should be
performed as described by the World
Health Organization, using a glucose
load containing the equivalent of 75 g
anhydrous glucose dissolved in water.
Testing for Pre-Diabetes and
Diabetes in Asymptomatic Patients
● Testing to detect pre-diabetes and type
2 diabetes in asymptomatic people
should be considered in adults of any
age who are overweight or obese (BMI
25kg/m
2)andwhohaveoneormore
additional risk factors for diabetes). In
those without these risk factors, testing
should begin at age 45 years. (B)
● Iftestsarenormal,repeattestingshould
be carried out at least at 3-year inter-
vals. (E)
● To test for pre-diabetes or diabetes, an
FPG test or 2-h OGTT (75-g glucose
load) or both are appropriate. (B)
● An OGTT may be considered in pa-
tients with impaired fasting glucose
(IFG) to better deﬁne the risk of diabe-
tes. (E)
● In those identiﬁed with pre-diabetes,
identify and, if appropriate, treat other
cardiovascular disease (CVD) risk fac-
tors. (B)
Testing for Type 2 Diabetes in
Children
● Test children who are overweight (BMI
85th percentile for age and sex,
weight for height 85th percentile, or
weight 120% of ideal for height) and
have any two of the following risk fac-
tors:
● Family history of type 2 diabetes in
ﬁrst- or second-degree relative
● Race/ethnicity of Native American,
African American, Latino, Asian
American, or Paciﬁc Islander
● Signs of insulin resistance or condi-
tions associated with insulin resis-
tance (acanthosis nigricans,
hypertension, dyslipidemia, polycys-
tic ovary syndrome, or small-for-
gestational-age birth weight)
● Maternal history of diabetes or gesta-
tional diabetes mellitus (GDM) dur-
ing the child’s gestation (E)
● Testing should begin at age 10 years
or at onset of puberty, if puberty oc-
curs at a younger age, and be re-
peated every 3 years. (E)
● FPG is the preferred test. (E)
Detection and Diagnosis of GDM
● Screen for GDM using risk factor anal-
ysis and, if appropriate, use of an
OGTT. (C)
● Women with GDM should be screened
for diabetes 6–12 weeks postpartum
and should be followed up with subse-
quent screening for the development of
diabetes or pre-diabetes. (E)
Prevention/Delay of Type 2 Diabetes
● Patients with impaired glucose toler-
ance (A) or IFG (E) should be referred
to an effective ongoing support pro-
gram for weight loss of 5–10% of body
weight and increasing physical activity
to at least 150 min per week of moder-
ate activity such as walking.
● Follow-upcounselingappearstobeim-
portant for success. (B)
● Based on potential cost savings of diabe-
tes prevention, such counseling should
be covered by third-party payors. (E)
Glucose Monitoring
● Self-monitoring of blood glucose
(SMBG) should be carried out three or
moretimesdailyforpatientsusingmul-
tiple insulin injections or insulin pump
therapy. (A)
● For patients using less frequent insulin
injections, noninsulin therapies, or
medical nutrition therapy (MNT) and
physical activity alone, SMBG may be
useful as a guide to the success of ther-
apy. (E)
● To achieve postprandial glucose tar-
gets,postprandialSMBGmaybeappro-
priate. (E)
● When prescribing SMBG, ensure that
patients receive initial instruction in,
and routine follow-up evaluation of,
SMBGtechniqueandtheirabilitytouse
data to adjust therapy. (E)
● Continuousglucosemonitoring(CGM)
in conjunction with intensive insulin
regimens can be a useful tool to lower
A1C in selected adults (aged 25
years) with type 1 diabetes (A).
● Although evidence for A1C lowering is
less strong in children, teens, and
younger adults, CGM may be helpful in
these groups. Success correlates with ad-
herence to ongoing use of the device. (C)
● CGM may be a supplemental tool to
SMBG in those with hypoglycemia un-
awareness and/or frequent hypoglyce-
mic episodes. (E)
A1C
● Perform the A1C test at least two times
ayearinpatientswhoaremeetingtreat-
ment goals (and who have stable glyce-
mic control). (E)
● Perform the A1C test quarterly in pa-
tients whose therapy has changed or
whoarenotmeetingglycemicgoals.(E)
● Use of point-of-care testing for A1C al-
lows for timely decisions on therapy
changes, when needed. (E)
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● Lowering A1C to below or around 7%
has been shown to reduce microvascu-
lar and neuropathic complications of
type 1 and type 2 diabetes. Therefore,
for microvascular disease prevention,
the A1C goal for nonpregnant adults in
general is 7%. (A)
● In type 1 and type 2 diabetes, random-
izedcontrolledtrialsofintensiveversus
standard glycemic control have not
shown a signiﬁcant reduction in CVD
outcomes during the randomized por-
tion of the trials. Long-term follow-up
of the Diabetes Control and Complica-
tions Trial (DCCT) and UK Prospective
Diabetes Study (UKPDS) cohorts sug-
gests that treatment to A1C targets be-
low or around 7% in the years soon
after the diagnosis of diabetes is associ-
atedwithlong-termreductioninriskof
macrovascular disease. Until more evi-
dence becomes available, the general
goal of 7% appears reasonable for
many adults for macrovascular risk re-
duction. (B)
● Subgroupanalysesofclinicaltrialssuch
as the DCCT and UKPDS and the mi-
crovascular evidence from the AD-
VANCE (Action in Diabetes and
Vascular Disease: Preterax and Diami-
cron MR Controlled Evaluation) trial
suggest a small but incremental beneﬁt
in microvascular outcomes with A1C
values closer to normal. Therefore, for
selected individual patients, providers
might reasonably suggest even lower
A1C goals than the general goal of
7%, if this can be achieved without
signiﬁcant hypoglycemia or other ad-
verseeffectsoftreatment.Suchpatients
might include those with short dura-
tion of diabetes, long life expectancy,
and no signiﬁcant CVD. (B)
● Conversely, less stringent A1C goals
than the general goal of 7% may be
appropriate for patients with a history
of severe hypoglycemia, limited life ex-
pectancy, advanced microvascular or
macrovascular complications, and ex-
tensive comorbid conditions and those
with longstanding diabetes in whom
the general goal is difﬁcult to attain de-
spite diabetes self-management educa-
tion, appropriate glucose monitoring,
and effective doses of multiple glucose-
lowering agents including insulin. (C)
Medical Nutrition Therapy (MNT)
General recommendations
● Individuals who have pre-diabetes or
diabetes should receive individualized
MNT as needed to achieve treatment
goals, preferably provided by a regis-
tereddietitianfamiliarwiththecompo-
nents of diabetes MNT. (B)
● MNT should be covered by insurance
and other payors. (E)
Energy balance, overweight, and obesity
● In overweight and obese insulin-
resistant individuals, modest weight
loss has been shown to reduce insulin
resistance. Thus, weight loss is recom-
mended for all overweight or obese in-
dividuals who have or are at risk for
diabetes. (A)
● For weight loss, either low-carbohy-
drate or low-fat calorie-restricted diets
may be effective in the short-term (up
to 1 year) (A).
● Forpatientsonlow-carbohydratediets,
monitor lipid proﬁles, renal function,
and protein intake (in those with ne-
phropathy) and adjust hypoglycemic
therapy as needed. (E)
● Physical activity and behavior modiﬁca-
tionareimportantcomponentsofweight
loss programs and are most helpful in
maintenance of weight loss. (B)
Primary prevention of diabetes
● Among individuals at high risk for de-
veloping type 2 diabetes, structured
programs that emphasize lifestyle
changes and include moderate weight
loss (7% body weight) and regular
physical activity (150 min/week), with
dietary strategies including reduced
calories and reduced intake of dietary
fat, can reduce the risk for developing





tion for dietary ﬁber (14 g ﬁber/1,000
kcal) and foods containing whole grains
(one-half of grain intake). (B)
Dietary fat intake in diabetes manage-
ment
● Saturated fat intake should be 7% of
total calories. (A)
● Intakeoftransfatshouldbeminimized.(B)
Carbohydrate intake in diabetes man-
agement
● Monitoring carbohydrate, whether by
carbohydrate counting, exchanges, or
experience-basedestimation,remainsa
key strategy in achieving glycemic con-
trol. (A)
● Forindividualswithdiabetes,theuseof
the glycemic index and glycemic load
may provide a modest additional bene-
ﬁt for glycemic control over that ob-
served when total carbohydrate is
considered alone. (B)
Other nutrition recommendations
● Sugar alcohols and nonnutritive sweet-
eners are safe when consumed within
the acceptable daily intake levels estab-
lished by the Food and Drug Adminis-
tration. (A)
● If adults with diabetes choose to use
alcohol, daily intake should be limited
to a moderate amount (one drink per
day or less for adult women and two
drinks per day or less for adult men).
(E)
● Routine supplementation with antioxi-
dants, such as vitamins E and C and
carotene, is not advised because of lack
of evidence of efﬁcacy and concern re-
lated to long-term safety. (A)
● Beneﬁt from chromium supplementa-
tion in people with diabetes or obesity
has not been conclusively demon-
strated and, therefore, cannot be rec-
ommended. (E)
Bariatric Surgery
● Bariatric surgery should be considered
for adults with BMI 35 kg/m
2 and
type 2 diabetes, especially if the diabe-
tes is difﬁcult to control with lifestyle
and pharmacologic therapy. (B)
● Patients with type 2 diabetes who have
undergone bariatric surgery need life-
long lifestyle support and medical
monitoring. (E)
● Although small trials have shown gly-
cemic beneﬁt of bariatric surgery in pa-
tients with type 2 diabetes and BMI of
30–35 kg/m
2, there is currently insuf-
ﬁcient evidence to generally recom-
mendsurgeryinpatientswithBMI35
kg/m
2 outside of a research protocol.
(E)
● The long-term beneﬁts, cost-
effectiveness, and risks of bariatric sur-
gery in individuals with type 2 diabetes
shouldbestudiedinwell-designedran-
domized controlled trials with optimal




● People with diabetes should receive
DSME according to national standards
when their diabetes is diagnosed and as
needed thereafter. (B)
● Self-management behavior change is
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be measured and monitored as part of
care. (E)
● DSME should address psychosocial is-
sues, since emotional well-being is
strongly associated with positive diabe-
tes outcomes. (C)
● DSME should be reimbursed by third-
party payors. (E)
Physical Activity
● People with diabetes should be advised
to perform at least 150 min/week of
moderate-intensity aerobic physical ac-
tivity (50–70% of maximum heart
rate). (A)
● In the absence of contraindications,
people with type 2 diabetes should be
encouragedtoperformresistancetrain-
ing three times per week. (A)
Psychosocial Assessment and Care
● Assessment of psychological and social
situation should be included as an on-
going part of the medical management
of diabetes. (E)
● Psychosocial screening and follow-up
should include, but is not limited to,
attitudes about the illness, expectations
for medical management and out-
comes, affect/mood, general and diabe-
tes-related quality of life, resources
(ﬁnancial, social, and emotional), and
psychiatric history. (E)
● Screen for psychosocial problems such
as depression, anxiety, eating disor-
ders, and cognitive impairment when
adherence to the medical regimen is
poor. (E)
Hypoglycemia
● Glucose (15–20 g) is the preferred
treatment for the conscious individual
with hypoglycemia, although any form
of carbohydrate that contains glucose
may be used. If SMBG 15 min after
treatment shows continued hypoglyce-
mia, the treatment should be repeated.
Once SMBG glucose returns to normal,
the individual should consume a meal
orsnacktopreventrecurrenceofhypo-
glycemia. (E)
● Glucagon should be prescribed for all
individuals at signiﬁcant risk of severe
hypoglycemia, and caregivers or family
membersoftheseindividualsshouldbe
instructed in its administration. Gluca-
gon administration is not limited to
health care professionals. (E)
● Individuals with hypoglycemia un-
awareness or one or more episodes of
severehypoglycemiashouldbeadvised
to raise their glycemic targets to strictly
avoid further hypoglycemia for at least
several weeks to partially reverse hypo-
glycemia unawareness and reduce risk
of future episodes. (B)
Immunization
● Annually provide an inﬂuenza vaccine
to all diabetic patients 6 months of
age. (C)
● Administer pneumococcal polysaccha-
ride vaccine to all diabetic patients 2
yearsofage.Aone-timerevaccinationis
recommended for individuals 64
years of age previously immunized
when they were 65 years of age if the
vaccine was administered 5 years
ago. Other indications for repeat vacci-
nation include nephrotic syndrome,
chronic renal disease, and other immu-





● Blood pressure should be measured at
every routine diabetes visit. Patients
found to have systolic blood pressure
130 mmHg or diastolic blood pres-
sure 80 mmHg should have blood
pressure conﬁrmed on a separate day.
Repeat systolic blood pressure 130
mmHgordiastolicbloodpressure80




to a systolic blood pressure 130
mmHg. (C)
● Patientswithdiabetesshouldbetreated
to a diastolic blood pressure 80
mmHg. (B)
Treatment
● Patients with a systolic blood pressure
of 130–139 mmHg or a diastolic blood
pressureof80–89mmHgmaybegiven
lifestyle therapy alone for a maximum
of 3 months and then, if targets are not
achieved,treatedwithadditionofphar-
macological agents. (E)
● Patients with more severe hypertension
(systolic blood pressure 140 or dia-
stolic blood pressure 90 mmHg) at
diagnosis or follow-up should receive
pharmacologic therapy in addition to
lifestyle therapy. (A)
● Pharmacologic therapy for patients
with diabetes and hypertension should
be with a regimen that includes either
an ACE inhibitor or an angiotensin re-
ceptor blocker (ARB). If one class is not
tolerated, the other should be substi-
tuted. If needed to achieve blood pres-
sure targets, a thiazide diuretic should
be added to those with an estimated
glomerularﬁltrationrate(GFR)(seebe-
low) 30 ml/min per 1.73 m
2 and a
loop diuretic for those with an esti-
mated GFR 30 ml/min per 1.73 m
2.
(C)
● Multiple drug therapy (two or more
agents at maximal doses) is generally




sium levels should be closely moni-
tored. (E)
● In pregnant patients with diabetes and
chronic hypertension, blood pressure
target goals of 110–129/65–79 mmHg
are suggested in the interest of long-
term maternal health and minimizing
impaired fetal growth. ACE inhibitors




● In most adult patients, measure fasting
lipid proﬁle at least annually. In adults
with low-risk lipid values (LDL choles-
terol 100 mg/dl, HDL cholesterol
50 mg/dl, and triglycerides 150
mg/dl), lipid assessments may be re-
peated every 2 years. (E)
Treatmentrecommendationsandgoals
● Lifestyle modiﬁcation focusing on the
reduction of saturated fat, trans fat, and
cholesterol intake; weight loss (if indi-
cated); and increased physical activity
should be recommended to improve
the lipid proﬁle in patients with diabe-
tes. (A)
● Statin therapy should be added to life-
style therapy, regardless of baseline
lipid levels, for diabetic patients:
● with overt CVD (A)
● without CVD who are over the age of
40 years and have one or more other
CVD risk factors. (A)
● For patients at lower risk than those
mentioned above (e.g., without overt
CVD and under the age of 40 years),
statin therapy should be considered in
addition to lifestyle therapy if LDL cho-
lesterol remains above 100 mg/dl or in
those with multiple CVD risk factors
(E)
● In individuals without overt CVD, the
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100 mg/dl (2.6 mmol/l). (A)





above targets on maximal tolerated sta-
tin therapy, a reduction in LDL choles-
terol of 30–40% from baseline is an
alternative therapeutic goal. (A)
● Triglyceride levels 150 mg/dl (1.7
mmol/l) and HDL cholesterol 40
mg/dl (1.0 mmol/l) in men and 50
mg/dl(1.3mmol/l)inwomenaredesir-
able. However, LDL cholesterol–
targeted statin therapy remains the
preferred strategy. (C)
● If targets are not reached on maximally
tolerated doses of statins, combination
therapy using statins and other lipid-
lowering agents may be considered to
achieve lipid targets but has not been
evaluated in outcome studies for either
CVD outcomes or safety. (E)
● Statin therapy is contraindicated in
pregnancy. (E)
Antiplatelet Agents
● Use aspirin therapy (75–162 mg/day)
as a primary prevention strategy in
those with type 1 or type 2 diabetes at
increased cardiovascular risk, includ-
ing those who are 40 years of age or
whohaveadditionalriskfactors(family
history of CVD, hypertension, smok-
ing, dyslipidemia, or albuminuria). (C)
● Use aspirin therapy (75–162 mg/day)
as a secondary prevention strategy in
those with diabetes with a history of
CVD. (A)
● For patients with CVD and docu-
mented aspirin allergy, clopidogrel (75
mg/day) should be used. (B)
● Combination therapy with ASA (75–
162 mg/day) and clopidogrel (75 mg/
day) is reasonable for up to a year after
an acute coronary syndrome. (B)
● Aspirin therapy is not recommended in
people under 30 years of age, due to
lack of evidence of beneﬁt, and is con-
traindicatedinpatientsundertheageof
21 years because of the associated risk
of Reye’s syndrome. (E)
Smoking Cessation
● Advise all patients not to smoke. (A)
● Include smoking cessation counseling
and other forms of treatment as a rou-
tine component of diabetes care. (B)
Coronary Heart Disease (CHD)
Screening and Treatment
Screening
● In asymptomatic patients, evaluate risk
factors to stratify patients by 10-year
risk and treat risk factors accordingly.
(B)
Treatment
● In patients with known CVD, ACE in-
hibitor (C), aspirin (A), and statin ther-
apy (A) (if not contraindicated) should
be used to reduce the risk of cardiovas-
cular events.
● In patients with a prior myocardial in-
farction, add -blockers (if not contra-
indicated) to reduce mortality. (A)
● In patients 40 years of age with an-
other cardiovascular risk factor (hyper-
tension, family history, dyslipidemia,
microalbuminuria, cardiac autonomic
neuropathy, or smoking), aspirin and
statin therapy (if not contraindicated)
should be used to reduce the risk of
cardiovascular events. (B)
● In patients with coronary heart failure
(CHF), thiazolidinedione use is contra-
indicated. (C)
● Metforminmaybeusedinpatientswith
stable CHF if renal function is normal.
Itshouldbeavoidedinunstableorhos-




● To reduce the risk or slow the progres-
sion of nephropathy, optimize glucose
control. (A)
● To reduce the risk or slow the progres-
sion of nephropathy, optimize blood
pressure control. (A)
Screening
● Perform an annual test to assess urine
albumin excretion (UAE) in type 1 dia-
betic patients with diabetes duration of
5 years and in all type 2 diabetic pa-
tients, starting at diagnosis. (E)
● Measureserumcreatinineatleastannu-
ally in all adults with diabetes regard-
less of the degree of UAE. The serum
creatinine should be used to estimate
GFR and stage the level of chronic kid-




either ACE inhibitors or ARBs should
be used. (A)
● While there are no adequate head-to-
head comparisons of ACE inhibitors
and ARBs, there is clinical trial support
for each of the following statements:
● In patients with type 1 diabetes, with
hypertensionandanydegreeofalbu-
minuria, ACE inhibitors have been
showntodelaytheprogressionofne-
phropathy. (A)
● In patients with type 2 diabetes, hy-
pertension, and microalbuminuria,
both ACE inhibitors and ARBs have
been shown to delay the progression
to macroalbuminuria. (A)
● In patients with type 2 diabetes, hy-
pertension, macroalbuminuria, and
renal insufﬁciency (serum creatinine
1.5 mg/dl), ARBs have been shown
to delay the progression of nephrop-
athy. (A)
● If one class is not tolerated, the other
should be substituted. (E)
● Reduction of protein intake to 0.8–1.0
g   kg body wt
1   day
1 in individuals
with diabetes and the earlier stages of
CKD and to 0.8 g   kg body wt
1  
day
1 in the later stages of CKD may
improve measures of renal function
(UAE rate, GFR) and is recommended
(B)
● When ACE inhibitors, ARBs, or diuret-
ics are used, monitor serum creatinine
and potassium levels for the develop-
ment of acute kidney disease and hy-
perkalemia. (E)
● ContinuedmonitoringofUAEtoassess
both response to therapy and progres-
sion of disease is recommended. (E)
● Consider referral to a physician experi-
enced in the care of kidney disease
when there is uncertainty about the eti-
ology of kidney disease (active urine
sediment,absenceofretinopathy,rapid
decline in GFR), difﬁcult management




● To reduce the risk or slow the progres-
sion of retinopathy, optimize glycemic
control. (A)
● To reduce the risk or slow the progres-
sion of retinopathy, optimize blood
pressure control. (A)
Screening
● Adults and children aged 10 years or
older with type 1 diabetes should have
an initial dilated and comprehensive
eyeexaminationbyanophthalmologist
or optometrist within 5 years after the
onset of diabetes. (B)
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have an initial dilated and comprehen-
siveeyeexaminationbyanophthalmol-
ogist or optometrist shortly after the
diagnosis of diabetes. (B)
● Subsequent examinations for type 1
and type 2 diabetic patients should be
repeated annually by an ophthalmolo-
gistoroptometrist.Lessfrequentexams
(every 2–3 years) may be considered
following one or more normal eye ex-
ams. Examinations will be required
more frequently if retinopathy is pro-
gressing. (B)
● Women with preexisting diabetes who
are planning pregnancy or who have
become pregnant should have a com-
prehensive eye examination and be
counseled on the risk of development
and/or progression of diabetic retinop-
athy. Eye examination should occur in
the ﬁrst trimester with close follow-up





diabetic retinopathy (NPDR), or any
proliferative diabetic retinopathy
(PDR) to an ophthalmologist who is
knowledgeable and experienced in the
management and treatment of diabetic
retinopathy. (A)
● Laser photocoagulation therapy is indi-
cated to reduce the risk of vision loss in
patients with high-risk PDR, clinically
signiﬁcantmacularedema,andinsome
cases of severe NPDR. (A)
● The presence of retinopathy is not a
contraindication to aspirin therapy for
cardioprotection, as this therapy does




● All patients should be screened for dis-
talsymmetricpolyneuropathy(DPN)at
diagnosis and at least annually thereaf-
ter using simple clinical tests. (B)
● Electrophysiological testing is rarely
needed, except in situations where the
clinical features are atypical. (E)
● Screening for signs and symptoms of
cardiovascular autonomic neuropathy
shouldbeinstitutedatdiagnosisoftype
2 diabetes and 5 years after the diagno-
sis of type 1 diabetes. Special testing is
rarely needed and may not affect man-
agement or outcomes. (E)
● Medications for the relief of speciﬁc
symptoms related to DPN and auto-
nomic neuropathy are recommended,
as they improve the quality of life of the
patient. (E)
Foot care
● For all patients with diabetes, perform
an annual comprehensive foot exami-
nationtoidentifyriskfactorspredictive
of ulcers and amputations. The foot ex-
amination should include inspection,
assessment of foot pulses, and testing
for loss of protective sensation (10-g
monoﬁlament plus testing any one of:
vibration using 128-Hz tuning fork,
pinprick sensation, ankle reﬂexes, or
vibration perception threshold). (B)
● Providegeneralfootself-careeducation
to all patients with diabetes. (B)
● A multidisciplinary approach is recom-
mendedforindividualswithfootulcers
andhigh-riskfeet,especiallythosewith
a history of prior ulcer or amputation.
(B)
● Refer patients who smoke, have loss of
protective sensation and structural ab-
normalities, or have history of prior
lower-extremity complications to foot
care specialists for ongoing preventive
care and life-long surveillance. (C)
● Initial screening for peripheral arterial
disease (PAD) should include a history
for claudication and an assessment of
thepedalpulses.Considerobtainingan
ankle-brachialindex(ABI),asmanypa-
tients with PAD are asymptomatic. (C)
● Referpatientswithsigniﬁcantclaudica-
tion or a positive ABI for further vascu-
lar assessment and consider exercise,
medications, and surgical options. (C)
Children and Adolescents
Glycemic control
● Consider age when setting glycemic
goals in children and adolescents with
type1diabetes,withlessstringentgoals
for younger children. (E)
Nephropathy
● Annual screening for microalbumin-
uria, with a random spot urine sample
for microalbumin-to-creatinine ratio,
should be initiated once the child is 10
years of age and has had diabetes for 5
years. (E)
● Conﬁrmed, persistently elevated mi-
croalbumin levels on two additional
urine specimens should be treated with
anACEinhibitor,titratedtonormaliza-
tion of microalbumin excretion if pos-
sible. (E)
Hypertension
● Treatment of high-normal blood pres-
sure (systolic or diastolic blood pres-
sure consistently between the 90–95th
percentile for age, sex, and height)
should include dietary intervention
and exercise, aimed at weight control
and increased physical activity, if ap-
propriate.Iftargetbloodpressureisnot
reached with 6–12 months of lifestyle
intervention, pharmacologic treatment
should be initiated. (E)
● Pharmacologic treatment of high blood
pressure (systolic or diastolic blood
pressure consistently above the 95th
percentile for age, sex, and height or
consistently 130/80 mmHg for ado-
lescents) should be initiated along with
lifestyle intervention as soon as the di-
agnosis is conﬁrmed. (E)
● ACE inhibitors should be considered
for the initial treatment of hyperten-
sion. (E)
● The goal of treatment is a blood pres-
sureconsistently130/80orbelowthe
90thpercentileforage,sex,andheight,
whichever is lower. (E)
Dyslipidemia
Screening
● If there is a family history of hypercho-
lesterolemia (total cholesterol 240
mg/dl) or a cardiovascular event before
age 55 years, or if family history is un-
known, then a fasting lipid proﬁle
should be performed on children 2
years of age soon after diagnosis (after
glucose control has been established).
If family history is not of concern, then
the ﬁrst lipid screening should be per-
formedatpuberty(10years).Allchil-
dren diagnosed with diabetes at or after
pubertyshouldhaveafastinglipidpro-
ﬁle performed soon after diagnosis
(after glucose control has been estab-
lished). (E)
● Forbothage-groups,iflipidsareabnor-
mal, annual monitoring is recom-
mended. If LDL cholesterol values are
within the accepted risk levels (100
mg/dl [2.6 mmol/l]), a lipid proﬁle
should be repeated every 5 years. (E)
Treatment
● Initialtherapyshouldconsistofoptimi-
zation of glucose control and MNT
using a Step 2 American Heart Associ-
ation diet aimed at a decrease in the
amount of saturated fat in the diet. (E)
● Aftertheageof10years,theadditionof
a statin is recommended in patients
who, after MNT and lifestyle changes,
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mmol/l) or LDL cholesterol 130
mg/dl (3.4 mmol/l) and one or more
CVD risk factors. (E)
● The goal of therapy is an LDL choles-
terol value 100 mg/dl (2.6 mmol/l).
(E)
Retinopathy
● The ﬁrst ophthalmologic examination
should be obtained once the child is
10 years of age and has had diabetes
for 3–5 years. (E)
● After the initial examination, annual
routine follow-up is generally recom-
mended. Less frequent examinations
may be acceptable on the advice of an
eye care professional. (E)
Celiac disease
● Patients with type 1 diabetes should be
screened for celiac disease by measur-
ing tissue transglutaminase or anti-
endomysial antibodies, with
documentation of normal serum IgA
levels,soonafterthediagnosisofdiabe-
tes. (E)
● Testing should be repeated if growth
failure, failure to gain weight, weight
loss,orgastroenterologicsymptomsoc-
cur. (E)
● Consideration should be given to peri-
odic rescreening of asymptomatic indi-
viduals. (E)
● Children with positive antibodies
should be referred to a gastroenterolo-
gist for evaluation. (E)
● Children with conﬁrmed celiac disease
should have consultation with a dieti-
tian and placed on a gluten-free diet.
(E)
Hypothyroidism
● Patients with type 1 diabetes should be
screened for thyroid peroxidase and
thyroglobulin antibodies at diagnosis.
(E)
● Thyroid stimulating hormone (TSH)
concentrations should be measured af-
ter metabolic control has been estab-
lished. If normal, they should be
rechecked every 1- 2 years or if the pa-
tient develops symptoms of thyroid
dysfunction,thyromegaly,oranabnor-
mal growth rate. Free T4 should be
measured if TSH is abnormal. (E)
Preconception Care
● A1C levels should be as close to normal
as possible (7%) in an individual pa-
tient before conception is attempted.
(B)
● Starting at puberty, preconception
counseling should be incorporated in
the routine diabetes clinic visit for all
women of child-bearing potential. (C)
● Womenwithdiabeteswhoarecontem-
plating pregnancy should be evaluated
and, if indicated, treated for diabetic
retinopathy,nephropathy,neuropathy,
and CVD. (E)
● Medications used by such women
should be evaluated before conception,
since drugs commonly used to treat di-
abetes and its complications may be
contraindicated or not recommended
in pregnancy, including statins, ACE




tively intact, and have signiﬁcant life
expectancy should receive diabetes
treatment using goals developed for
younger adults. (E)
● Glycemic goals for older adults not
meeting the above criteria may be re-
laxed using individual criteria, but hy-
perglycemia leading to symptoms or
risk of acute hyperglycemic complica-
tions should be avoided in all patients.
(E)
● Other cardiovascular risk factors
should be treated in older adults with
consideration of the time frame of ben-
eﬁt and the individual patient. Treat-
ment of hypertension is indicated in
virtually all older adults, and lipid and
aspirin therapy may beneﬁt those with
lifeexpectancyatleastequaltothetime
frame of primary or secondary preven-
tion trials. (E)
● Screening for diabetes complications
should be individualized in older
adults, but particular attention should
be paid to complications that would
lead to functional impairment. (E)
Diabetes Care in the Hospital
● All patients with diabetes admitted to
the hospital should have their diabetes
clearly identiﬁed in the medical record.
(E)
● All patients with diabetes should have
an order for blood glucose monitoring,
with results available to all members of
the health care team. (E)
● Goals for blood glucose levels:
● Critically ill surgical patients’ blood
glucose levels should be kept as close
to110mg/dl(6.1mmol/l)aspossible
and generally 140 mg/dl (7.8
mmol/l). (A) These patients require
an intravenous insulin protocol that
has demonstrated efﬁcacy and safety
in achieving the desired glucose
range without increasing risk for se-
vere hypoglycemia. (E)
● Criticallyillnonsurgicalpatients’glyce-
mic targets are less well deﬁned. Intra-
venous insulin infusion protocols
targeting blood glucose levels 110–
140 mg/dl have been shown to re-
ducedmorbidityandmortalityinsome
but not all studies. Intravenous insulin
infusion protocols that effectively and
safely keep blood glucose 140 mg/dl
are recommended. (C)
● Non–criticallyillpatients:thereisno
clear evidence for speciﬁc blood glu-
cose goals. Since cohort data suggest
that outcomes are better in hospital-
ized patients with fasting glucose
126 mg/dl and all random glucose
levels180–200,thesegoalsarerea-
sonableiftheycanbesafelyachieved.
Insulin is the preferred drug to treat
hyperglycemia in most cases. (E)
● Due to concerns regarding the risk of
hypoglycemia, some institutions may
consider these blood glucose levels to
be overly aggressive for initial targets.
Through quality improvement, glyce-
mic goals should systematically be re-
duced to the recommended levels. (E)
● Scheduled prandial insulin doses should
be appropriately timed in relation to
meals and should be adjusted according
to point-of-care glucose levels. The tradi-
tional sliding-scale insulin regimens are
ineffective as monotherapy and are gen-
erally not recommended. (C)
● Using correction dose or “supplemen-
tal” insulin to correct premeal hyper-
glycemia in addition to scheduled
prandial and basal insulin is recom-
mended. (E)
● Glucose monitoring with orders for cor-
rection insulin should be initiated in any
patient not known to be diabetic who re-
ceives therapy associated with high risk
for hyperglycemia, including high-dose
glucocorticoid therapy, initiation of en-
teral or parenteral nutrition, or other
medications such as octreotide or immu-
nosuppressive medications. (B) If hyper-
glycemia is documented and persistent,
initiation of basal/bolus insulin therapy
may be necessary. Such patients should
be treated to the same glycemic goals as
patients with known diabetes. (E)
● A plan for treating hypoglycemia
should be established for each patient.
Episodes of hypoglycemia in the hospi-
tal should be tracked. (E)
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the hospital should have an A1C ob-
tained if the result of testing in the pre-
vious 2–3 months is not available. (E)
● Adiabeteseducationplanincluding“sur-
vival skills education” and follow-up
shouldbedevelopedforeachpatient.(E)
● Patientswithhyperglycemiainthehos-
pital who do not have a diagnosis of
diabetes should have appropriate plans
for follow-up testing and care docu-
mented at discharge. (E)
Diabetes Care in the School and Day
Care Setting
● An individualized Diabetes Medical
Management Plan (DMMP) should be
developed by the parent/guardian and
the student’s personal diabetes health
care team with input from the parent/
guardian. (E)
● All school staff members who have re-
sponsibility for a student with diabetes
should receive training that provides a
basic understanding of diabetes and a
student’s needs. (E)
● Whiletheschoolnurseisthecoordinator
and primary provider of diabetes care, a
smallnumberofschoolpersonnelshould
be trained in routine and emergency dia-
betes procedures (including monitoring
of blood glucose levels and administra-
tion of insulin and glucagon) and in the
appropriate response to high and low
blood glucose levels and should perform
these diabetes care tasks when the school
nurse is not available to do so. These
school personnel need not be health care
professionals. (E)
● AsspeciﬁedintheDMMPandasdevel-
opmentally appropriate, the student
with diabetes should have immediate
access to diabetes supplies at all times
andshouldbepermittedtoself-manage
his or her diabetes in the classroom or
anywhere the student may be in con-
junction with a school activity. Such
self-management should include blood
glucose monitoring and responding to
blood glucose levels with needed food
and medication. (E)
Diabetes Care at Diabetes Camps
● Each camper should have a standard-
izedmedicalformcompletedbyhis/her
family and the physician managing the
diabetes. (E)
● Camp medical staff should be led by a
physician with expertise in managing
type 1 and type 2 diabetes and should
include nurses (including diabetes ed-
ucators and diabetes clinical nurse spe-
cialists) and registered dietitians with
expertise in diabetes. (E)
● All camp staff, including physicians,
nurses, dietitians, and volunteers,
should undergo background testing to




● Correctional staff should be trained in
the recognition, treatment, and appro-
priate referral for hypo- and hypergly-
cemia, including serious metabolic
decompensation. (E)
● Patients with a diagnosis of diabetes
shouldhaveacompletemedicalhistory
and physical examination by a licensed
health care provider with prescriptive
authority in a timely manner upon en-
try. Insulin-treated patients should
have a capillary blood glucose (CBG)
determination within 1–2 h of arrival.
Staff should identify patients with type
1 diabetes who are at high risk for dia-
betic ketoacidosis with omission of in-
sulin. (E)
● Medications and MNT should be con-
tinuedwithoutinterruptionuponentry
into the correctional environment. (E)
● In the correctional setting, policies and
procedures should enable CBG moni-
toring to occur at the frequency neces-
sitatedbythepatient’sglycemiccontrol
and diabetes regimen and should re-
quire staff to notify a physician of all
CBG results outside of a speciﬁed
range, as determined by the treating
physician. (E)
● For all inter-institutional transfers, a
medical transfer summary should be
transferred with the patient, and diabe-
tes supplies and medication should ac-
company the patient. (E)
● Correctional staff should begin dis-
charge planning with adequate lead
time to ensure continuity of care and




● People with diabetes should maintain a
disaster kit that includes items impor-
tant to their diabetes self-management
and continuing medical care. (E)
● The kit should be reviewed and replen-
ished at least twice yearly. (E)
Diabetes and Employment
● When questions arise about the medical
ﬁtnessofapersonwithdiabetesforapar-
ticularjob,ahealthcareprofessionalwith




● Proper safety assessments for employ-
ment should include review of blood
glucose test results, history of severe
hypoglycemia, presence of hypoglyce-
mia unawareness, and presence of dia-
betes-related complications but should
not include urine glucose or A1C/eAG
(estimated average glucose) tests or be





● Patients and practitioners should
have access to all classes of antidiabe-
tes medications, equipment, and sup-
plies without undue controls. (E)
● MNT and DSME should be covered by
insurance and other payors. (E)
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